NYSE : CAH
$2.96 (1.3%)
| Source | Headline |
|---|---|
|
Here is Why Growth Investors Should Buy Cardinal (CAH) Now
Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials. zacks.com - 2026-07-30 13:46:07 |
|
Why Cardinal Health (CAH) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com - 2026-07-30 10:45:47 |
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now. zacks.com - 2026-07-29 09:56:27 |
|
Why Cardinal Health (CAH) Outpaced the Stock Market Today
In the most recent trading session, Cardinal Health (CAH) closed at $232.51, indicating a +1.38% shift from the previous trading day. zacks.com - 2026-07-28 19:01:44 |
|
Cardinal Health Expands Home Care Business With Two Acquisitions
CAH is set to buy two home-care businesses for about $360 million, expanding diabetes and urology reach while targeting first-year EPS accretion. zacks.com - 2026-07-22 13:21:10 |
|
Should Value Investors Buy Cardinal Health (CAH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 2026-07-22 10:41:09 |
|
Here's Why Cardinal Health (CAH) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 2026-07-21 10:51:08 |
|
Cardinal Health (CAH) Registers a Bigger Fall Than the Market: Important Facts to Note
Cardinal Health (CAH) reached $225.75 at the closing of the latest trading day, reflecting a -1.21% change compared to its last close. zacks.com - 2026-07-20 19:01:15 |
|
Cardinal Health to buy AdaptHealth diabetes unit, Strive Medical for $360 million
Cardinal Health said on Monday it has agreed to buy AdaptHealth's diabetes health business and medical supply provider Strive Medical in separate deals for about $360 million in total, expanding its home care business. reuters.com - 2026-07-20 17:23:46 |
|
Cardinal Health expands home care business with two tuck-in acquisitions
DUBLIN, Ohio, July 20, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today it has entered into two definitive agreements that accelerate its at-Home Solutions' growth strategy. Cardinal Health will acquire the Diabetes Health business of AdaptHealth Corp. (NASDAQ: AHCO), and, in its entirety, Strive Medical, a multi-specialty supply provider with a focus on urology. prnewswire.com - 2026-07-20 16:45:00 |
|
Cardinal Health (CAH) Stock Sinks As Market Gains: Here's Why
In the closing of the recent trading day, Cardinal Health (CAH) stood at $230.11, denoting a -1.52% move from the preceding trading day. zacks.com - 2026-07-14 19:01:14 |
|
Zacks Industry Outlook McKesson, Cardinal, West Pharmaceutical, Align and Henry
McKesson, Cardinal, West Pharmaceutical, Align and Henry have been highlighted in this Industry Outlook article. zacks.com - 2026-07-14 04:36:12 |
|
Looking for a Growth Stock? 3 Reasons Why Cardinal (CAH) is a Solid Choice
Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials. zacks.com - 2026-07-13 13:46:09 |
|
5 Medical Supply Stocks to Buy Amid Strong Industry Tailwinds
Here, we highlight five dental supplies stocks, MCK, CAH, WST, ALGN and HSIC, which are well positioned to generate wealth for investors amid improving industry prospect. zacks.com - 2026-07-13 13:40:24 |
|
Why Cardinal (CAH) is Poised to Beat Earnings Estimates Again
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. zacks.com - 2026-07-13 13:10:17 |
|
Here's Why Cardinal Health (CAH) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com - 2026-07-13 10:46:10 |
|
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. zacks.com - 2026-07-13 09:56:21 |
|
Wall Street Analysts See Cardinal (CAH) as a Buy: Should You Invest?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. zacks.com - 2026-07-10 10:30:36 |
|
Should You Retain CAH Stock After Removal From Several Russell Indices?
CAH's Russell index removal reflects reclassification after its share rally, while specialty growth and resilient operations continue supporting its long-term outlook. zacks.com - 2026-07-09 15:26:07 |
|
Cardinal Health to Announce Fourth-Quarter and Year-End Results for Fiscal Year 2026 on August 11
DUBLIN, Ohio, July 9, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release fourth-quarter and year-end financial results for its fiscal year 2026 on August 11, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. prnewswire.com - 2026-07-09 06:45:00 |
|
Cardinal Health (CAH) Declines More Than Market: Some Information for Investors
Cardinal Health (CAH) concluded the recent trading session at $237.15, signifying a -1.07% move from its prior day's close. zacks.com - 2026-07-08 19:16:11 |
|
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion. fool.com - 2026-07-06 13:09:01 |
|
Cardinal Health: Why This Essential Healthcare Distributor Deserves A Buy Rating
Cardinal Health receives a Buy rating, supported by defensive business fundamentals, strong adjusted EPS growth, and strategic expansion into specialty healthcare. CAH's Q3FY26 showed 11% revenue growth and 35% adjusted EPS growth, though GAAP results were pressured by higher costs and special items. Valuation is at a premium with a Forward P/E of 21.64x, justified by improving profitability and cash flow, but future upside depends on sustained margin gains. seekingalpha.com - 2026-07-03 14:55:14 |
|
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com - 2026-07-03 10:41:16 |
|
Why Cardinal Health (CAH) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com - 2026-07-02 10:51:11 |
|
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 2026-07-01 10:41:21 |
|
Why the Market Dipped But Cardinal Health (CAH) Gained Today
Cardinal Health (CAH) closed at $237.92 in the latest trading session, marking a +1.35% move from the prior day. zacks.com - 2026-06-26 19:02:14 |
|
Cardinal Health, Inc. (CAH) Hits Fresh High: Is There Still Room to Run?
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com - 2026-06-25 10:16:07 |
|
Cardinal Health (CAH) Ascends While Market Falls: Some Facts to Note
In the latest trading session, Cardinal Health (CAH) closed at $233.01, marking a +1.79% move from the previous day. zacks.com - 2026-06-24 19:16:31 |
|
Here's Why Cardinal Health (CAH) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com - 2026-06-19 10:47:11 |
|
CAH Stock Up Nearly 8% YTD: Will the Uptrend Continue in the Rest of 2026?
Cardinal Health has gained nearly 8% in 2026 as specialty pharma growth, rising EPS, and expanding healthcare services fuel investor optimism. zacks.com - 2026-06-19 09:40:40 |
|
Cardinal Health (CAH) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Cardinal Health (CAH) stood at $221.77, denoting a -1.99% move from the preceding trading day. zacks.com - 2026-06-18 19:01:11 |
|
Is It Worth Investing in Cardinal (CAH) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? zacks.com - 2026-06-18 10:30:58 |
|
The Healthcare M&A Wave
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here. forbes.com - 2026-06-17 12:30:08 |
|
Here's Why Cardinal Health (CAH) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com - 2026-06-17 10:40:27 |
|
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
Androstenedione and other adrenal hormone levels in 11β‑hydroxylase-deficient patients improved substantially after initiation of CRENESSITY, with >90% median reductions in 11-deoxycortisol and 11-deoxycorticosterone Nearly all patients (14/15) reduced their total glucocorticoid dose with CRENESSITY, and 2 of 5 patients on antihypertensive medications reduced or discontinued these drugs Findings provide initial clinical insights in patients with classic congenital adrenal hyperplasia due to 11β-hydroxylase deficiency, a rare subtype not previously studied in clinical trials of CRENESSITY SAN DIEGO, June 15, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced clinical findings from the first retrospective case series in pediatric and adult patients with classic congenital adrenal hyperplasia (CAH) due to 11β‑hydroxylase deficiency. This subtype was not previously studied in clinical trials of CRENESSITY® (crinecerfont) and is the second most common form of classic CAH after 21-hydroxylase deficiency, accounting for approximately 5% of cases. prnewswire.com - 2026-06-15 16:05:00 |
|
Is Cardinal Health (CAH) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 2026-06-12 10:41:11 |
|
Cardinal Health Inc (CAH) Shares Surge 3.0% -- What GF Score of 85 Tells Investors
On June 04, 2026, Cardinal Health Inc (CAH) shares rose 3.0%, bringing the current price to $201.74. The stock has traded within a 52-week range of $137.75 to $ gurufocus.com - 2026-06-04 17:41:00 |
|
Wall Street Analysts Predict a 25.75% Upside in Cardinal (CAH): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Cardinal (CAH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com - 2026-06-01 10:56:17 |
|
Here's Why Cardinal Health (CAH) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com - 2026-06-01 10:42:35 |
|
CAH vs. COR: Which Healthcare Distributor Stock Is the Better Buy?
CAH and COR are betting big on specialty pharma, but Cardinal Health???s stronger growth, raised outlook, and broader expansion may set it apart. zacks.com - 2026-05-27 12:11:13 |
|
Why Cardinal Health (CAH) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com - 2026-05-27 10:47:06 |
|
Is Cardinal Health (CAH) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 2026-05-27 10:40:29 |
|
Is Cardinal (CAH) a Buy as Wall Street Analysts Look Optimistic?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. zacks.com - 2026-05-27 10:30:34 |
|
Can CAH's Surging Other Growth Businesses Become Its Next Profit Engine?
CAH's fast-growing Other Growth Businesses posted 34% revenue growth and 52% profit gains, raising their role in long-term earnings. zacks.com - 2026-05-25 12:16:05 |
|
Cardinal Health (CAH) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 2026-05-25 10:51:14 |
|
Here's Why You Should Add Cardinal Health Stock to Your Portfolio Now
Cardinal Health's specialty growth, strong cash flow and expanding higher-margin businesses are boosting earnings momentum despite IRA and GMPD risks. zacks.com - 2026-05-20 15:35:24 |
|
3 Reasons Why Growth Investors Shouldn't Overlook Cardinal (CAH)
Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market. zacks.com - 2026-05-20 13:45:14 |
|
April 2026 Dividend Income Report - An Insane 80% Dividend Growth Rate
April 2026 delivered another major milestone for the portfolio. We posted an insane 80% year-over-year increase. In April 2026, I received $1,742.78 in dividend income compared to $968.18 in April 2025. Looking beyond just April, the full 2026 dividend income picture continues to trend dramatically ahead of 2025. The portfolio is producing significantly more cash flow through the first four months of the year. seekingalpha.com - 2026-05-19 15:45:00 |
|
Is CAH Becoming the Backbone of US Healthcare Infrastructure?
Cardinal Health is expanding beyond drug distribution into specialty care, logistics and nuclear medicine, deepening its role in US healthcare infrastructure. zacks.com - 2026-05-19 15:30:50 |